Stock Price & Analysis

Based on the current technical indicators and recent news, SRPT shows mixed signals but leans towards a cautious buy recommendation at the current price of $112.67, with significant analyst support targeting a 56.5% upside potential, though investors should note the recent volatility following patient safety concerns.

The stock is currently trading near its Fibonacci support level of $110.66, suggesting a potential bounce point. The RSI at 40.86 indicates slightly oversold conditions but not extreme, while the negative MACD (-2.24) suggests some ongoing bearish momentum that warrants caution.

Recent positive catalysts include:

• Strong analyst consensus with multiple Buy ratings and price targets suggesting significant upside
• Clarification that recent patient death concerns were unrelated to treatment
• Solid preliminary Q4 revenue performance

Based on the provided data and recent market developments, here's the price prediction for SRPT stock in 2025:

SRPT is projected to reach $175-180 by end of 2025, driven by strong analyst consensus and positive clinical trial results for its gene therapy programs. The stock's current technical indicators showing RSI at 40.86 suggests it's approaching oversold territory, presenting a potential buying opportunity at current levels. Recent positive EMBARK study results and successful Elevidys commercialization support this bullish outlook.

The S1 support level for SRPT Stock is $110.66 ,The R1 resistant level for SRPT Stock is $118.7.

As of the end of day on 2025-02-11, the price of SRPT Stock was $110.36.

The target price for SRPT Stock according to analyst rating is 182.00, with the highest price target at 217.00 and the lowest at 75.00. Analysts have a Strong Buy rating on SRPT Stock overall.

The market cap of SRPT is $10.8B.

Based on the provided data and current market status (closed), here's a concise analysis of SRPT's valuation:

Technical Analysis

Valuation Assessment SRPT is currently trading at $112.74 with mixed valuation metrics. The stock shows high P/E ratios in recent quarters (Q3 2024: 81.71x), suggesting premium pricing relative to earnings. However, this has significantly decreased from Q1 2024's 311.97x, indicating improving earnings efficiency.

Analyst Sentiment Recent analyst opinions are notably divided:

• Needham maintains Strong Buy with $202 PT (69.99% upside)
• HC Wainwright reiterates Strong Sell with $75 PT (-34.05% downside)
• Overall analyst consensus shows a wide dispersion, reflecting significant uncertainty

Key Growth Drivers

• Elevidys's expanded approval and label expansion in June 2024 positions SRPT as a dominant player in DMD treatment market
• Manufacturing capacity expansion planned for 2026 to meet high demand expectations
• Diversification into Limb-Girdle Muscular Dystrophy through SRP-9003 development

Risk Factors

• Manufacturing capacity constraints until 2026
• High valuation multiples despite recent compression
• Wide analyst disagreement on valuation and prospects

Conclusion At current price levels, SRPT appears overvalued based on traditional metrics, but this view needs context:

• The company's recent label expansion and pipeline progress could justify premium pricing
• Significant analyst disagreement suggests high uncertainty
• The declining P/E trend indicates improving fundamentals

Sarepta Therapeutics, Inc. is a commercial-stage biopharmaceutical company. The Company is focused on helping patients through the discovery and development of ribonucleic acid (RNA)-targeted therapeutics, gene therapy and other genetic therapeutic modalities for the treatment of rare diseases. It has developed multiple approved products for the treatment of Duchenne muscular dystrophy (Duchenne) and is developing potential therapeutic candidates for a range of diseases and disorders, including Duchenne, Limb-girdle muscular dystrophies (LGMDs) and other neuromuscular and central nervous system (CNS) related disorders. It has developed and commercialized four approved products for the treatment of Duchenne: EXONDYS 51 (eteplirsen), Injection (EXONDYS 51), VYONDYS 53 (golodirsen) Injection (VYONDYS 53), AMONDYS 45 (casimersen) Injection (AMONDYS 45), and ELEVIDYS. Its pipeline includes approximately 40 programs at various stages of discovery, pre-clinical and clinical development.

Based on analyst projections and technical analysis, Sarepta Therapeutics (SRPT) stock is expected to reach $203 by 2030, driven by strong growth in its gene therapy portfolio and positive EMBARK study results showing sustained benefits. Recent analyst coverage from TD Cowen maintains a bullish outlook with a $203 price target, supported by all nine top analysts rating it as a Buy with an average upside of 56.5%. The company's successful commercialization of Elevidys and expanding pipeline in rare genetic diseases positions it for significant long-term growth potential.

SRPT has a total of 1314 employees.